Literature DB >> 2924317

Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.

D Colcher1, D Milenic, M Roselli, A Raubitschek, G Yarranton, D King, J Adair, N Whittle, M Bodmer, J Schlom.   

Abstract

B72.3 is a murine monoclonal antibody (IgG1) that recognizes a tumor-associated glycoprotein, termed TAG-72. B72.3 has been shown, using a variety of methodologies, to have a high degree of selective reactivity for colorectal, ovarian, lung, and breast carcinomas. Radiolabeled B72.3 has been administered both i.v. and i.p. in patients with colorectal and ovarian cancer as well as other carcinomas and has been shown to selectively bind to approximately 70-80% of metastatic lesions. Greater than 50% of the patients that have been treated with B72.3 have developed an immunological response to murine IgG after a single injection. In an attempt to minimize the immune response of these patients to the administered murine monoclonal antibody, we developed a recombinant form of the murine B72.3 as well as a recombinant/chimeric antibody, using the variable regions of the murine B72.3 and human heavy chain (gamma 4) and light chain (kappa) constant regions. We report here that both the recombinant B72.3 [rB72.3] and the recombinant/chimeric B72.3 [cB72.3(gamma 4)] IgGs maintain the tissue binding and idiotypic specificity of the native murine IgG. The native B72.3, rB72.3, and cB72.3(gamma 4) IgGs were radiolabeled and the biodistribution of these IgGs was studied in athymic mice bearing human colon carcinoma xenografts (LS-174T). Differences were observed between the cB72.3(gamma 4) and the native B72.3 in the percentage of injected dose/g that localized in the tumor. The somewhat lower absolute amounts of the cB72.3(gamma 4) in the tumor are mostly likely due to the observed more rapid clearance from the blood and body of the mouse as compared to the native B72.3 and rB72.3. All three forms [native B72.3, rB72.3, and cB72.3(gamma 4)] of the IgG, however, were able to localize the colon tumor with similar radiolocalization indices [percentage of injected dose/g in tumor divided by the percentage of injected dose/g in normal tissue].

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2924317

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Frequent anti-V-region immune response to mouse B72.3 monoclonal antibody.

Authors:  M B Khazaeli; M N Saleh; T Liu; P M Kaladas; S C Gilman; A F LoBuglio
Journal:  J Clin Immunol       Date:  1992-03       Impact factor: 8.317

2.  High affinity mouse-human chimeric Fab against hepatitis B surface antigen.

Authors:  Biplab Bose; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  World J Gastroenterol       Date:  2005-12-28       Impact factor: 5.742

3.  Expression, purification and characterization of a mouse-human chimeric antibody and chimeric Fab' fragment.

Authors:  D J King; J R Adair; S Angal; D C Low; K A Proudfoot; J C Lloyd; M W Bodmer; G T Yarranton
Journal:  Biochem J       Date:  1992-01-15       Impact factor: 3.857

4.  Generation and characterization of high affinity humanized fab against hepatitis B surface antigen.

Authors:  Ashutosh Tiwari; Durgashree Dutta; Navin Khanna; Subrat K Acharya; Subrata Sinha
Journal:  Mol Biotechnol       Date:  2009-03-27       Impact factor: 2.695

5.  Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites.

Authors:  J Schuurman; R Van Ree; G J Perdok; H R Van Doorn; K Y Tan; R C Aalberse
Journal:  Immunology       Date:  1999-08       Impact factor: 7.397

6.  Intrachain disulfide bond in the core hinge region of human IgG4.

Authors:  J W Bloom; M S Madanat; D Marriott; T Wong; S Y Chan
Journal:  Protein Sci       Date:  1997-02       Impact factor: 6.725

7.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2.

Authors:  B M Mueller; R A Reisfeld; S D Gillies
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

8.  Exploration of a F(ab')2 Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Authors:  Diane E Milenic; Young-Seung Kim; Kwamena E Baidoo; Karen J Wong; Rachel Barkley; Jose Delgado; Martin W Brechbiel
Journal:  Cancer Biother Radiopharm       Date:  2018-06       Impact factor: 3.099

Review 9.  IgG4 breaking the rules.

Authors:  Rob C Aalberse; Janine Schuurman
Journal:  Immunology       Date:  2002-01       Impact factor: 7.397

Review 10.  A comprehensive overview of radioguided surgery using gamma detection probe technology.

Authors:  Stephen P Povoski; Ryan L Neff; Cathy M Mojzisik; David M O'Malley; George H Hinkle; Nathan C Hall; Douglas A Murrey; Michael V Knopp; Edward W Martin
Journal:  World J Surg Oncol       Date:  2009-01-27       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.